NCI Initiates Phase 1 Trial for TNhYP218, a Mesothelin-Targeted CAR-T Therapy for Solid Tumors
Clinical Design and Development Stage
The National Cancer Institute (NCI) is conducting a Phase 1 clinical trial (NCT06885697) of TNhYP218, an autologous CAR-T therapy targeting mesothelin (MSLN)-positive solid tumors. TNhYP218, a non-commercial code name, is a T-naive/stem cell memory T-cell therapy that expresses a humanized hYP218 antibody-based chimeric antigen receptor, targeting an MSLN epitope located near the cell membrane. The trial began on July 8, 2025, and aims to enroll 100 patients at the NIH Clinical Center in Bethesda. Following dose escalation, a mesothelioma expansion cohort will be conducted at the recommended Phase 2 dose (RP2D). The primary completion date is projected for June 2034, and the long-term follow-up completion date is June 2044.
Structure Targeting Bottlenecks in Solid Tumor CAR-T
Unlike CAR-T therapies for hematological malignancies, solid tumors present challenges such as antigen heterogeneity, insufficient tumor penetration, and an immunosuppressive microenvironment, leading to T-cell exhaustion. TNhYP218 is designed to address these bottlenecks by targeting an epitope closer to the cell membrane than circulating MSLN and utilizing a T-naive/SCM fraction with enhanced persistence. Enrollment requires patients with at least 50% of cancer cells showing MSLN 2+ to 3+ expression on immunohistochemical testing, who have progressed after at least one standard treatment in an unresectable, locally advanced, metastatic, or recurrent state. Therefore, the key focus of the initial data will be dose-limiting toxicity (DLT), cell persistence, tumor penetration, and the establishment of the RP2D.
Standard Treatment and Competitive Landscape
The first-line standard treatment for mesothelioma includes the combination of Opdivo (nivolumab, a PD-1 inhibitor) and Yervoy (ipilimumab, a CTLA-4 inhibitor) from Bristol Myers Squibb (BMY), which was approved by the FDA on October 2, 2020. Keytruda (pembrolizumab, a PD-1 inhibitor) from Merck & Co. (MRK) in combination with pemetrexed and platinum-based chemotherapy also received FDA approval on September 17, 2024. In the cell therapy competitive landscape, there is a Phase 1 trial for BZDS1901, a mesothelin CAR-T therapy, and a Phase 1/2 trial for gavo-cel, developed by TCR2 Therapeutics and now part of Adaptimmune Therapeutics (ADAP). Although TNhYP218 is in an earlier stage of development compared to approved immune checkpoint inhibitors, its ability to target multiple MSLN-positive tumors with a single biomarker strategy is a key differentiator.
Market Potential and Execution Risks
The global market for malignant mesothelioma is projected to grow from USD 681.2 million in 2024 to USD 975.2 million in 2030. The trial also includes pancreatic, ovarian, lung, gastric, colorectal, and thymic cancers. However, the commercial potential depends more on demonstrating reproducible MSLN-targeting efficacy across various solid tumors than on the rare mesothelioma market itself. The autologous process, which requires leukapheresis, individualized manufacturing, fludarabine/cyclophosphamide lymphodepletion, and inpatient administration, limits cost and throughput. The 5-year clinical follow-up and additional 10-year long-term follow-up are regulatory requirements to assess the long-term safety of gene-modified cells. At this stage, manufacturing success rate and initial safety are prerequisites for value creation.
The Phase 1 trial, enrolling 100 patients, will evaluate the dose-limiting toxicity and recommended Phase 2 dose of TNhYP218, as well as whether the T-naive/SCM-based persistence can improve the penetration and exhaustion issues of CAR-T therapy in solid tumors in actual patients. The mesothelioma market is USD 681.2 million in 2024, and if efficacy is replicated in MSLN-positive pancreatic, ovarian, and lung cancers, the economic scope will expand significantly. In the short term, the key competitors are BMY's Opdivo/Yervoy and MRK's Keytruda/chemotherapy, which are approved as first-line treatments by the FDA, and the development competitors are BZDS1901 in Phase 1 and gavo-cel in Phase 1/2. In the medium to long term, the value will be determined by manufacturing success rate, cell persistence, MSLN selectivity in each tumor, and 15-year safety follow-up, rather than the depth of response. Given the early stage of the Phase 1 trial, a Watchlist rating is appropriate for investment decisions.
Source: ClinicalTrials.gov (api_ct)